1. |
Chorin E, Rozenbaum Z, Topilsky Y, et al. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging, 2020, 21(2): 157-165.
|
2. |
Asmarats L, Taramasso M, Rodés-Cabau J. Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field. Nat Rev Cardiol, 2019, 16(9): 538-554.
|
3. |
Topilsky Y, Maltais S, Medina Inojosa J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovascular Imaging, 2019, 12(3): 433-442.
|
4. |
Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardiovasc Surg, 2006, 132(6): 1258-1261.
|
5. |
Yang L, Chen H, Pan W, et al. Analyses for prevalence and outcome of tricuspid regurgitation in China: an echocardiography study of 134, 874 patients. Cardiology, 2019, 142(1): 40-46.
|
6. |
Benfari G, Antoine C, Miller WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation, 2019, 140(3): 196-206.
|
7. |
Chang JD, Manning WJ, Ebrille E, et al. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol, 2017, 69(18): 2331-2341.
|
8. |
Arsalan M, Walther T, Smith RL 2nd, et al. Tricuspid regurgitation diagnosis and treatment. Eur Heart J. 2017, 38(9): 634-638.
|
9. |
袁祖贻, 陈绍良. 心脏病学实践2021(全7册): 第五分册结构性心脏病. 北京: 人民卫生出版社, 2021: 75-89.
|
10. |
Dhoble A, Zhao Y, Vejpongsa P, et al. National 10-year trends and outcomes of isolated and concomitant tricuspid valve surgery. J Cardiovasc Surg (Torino), 2019, 60(1): 119-127.
|
11. |
Dreyfus J, Ghalem N, Garbarz E, et al. Timing of referral of patients with severe isolated tricuspid valve regurgitation to surgeons (from a french nationwide database). Am J Cardiol, 2018, 122(2): 323-326.
|
12. |
Alqahtani F, Berzingi CO, Aljohani S, et al. Contemporary trends in the use and outcomes of surgical treatment of tricuspid regurgitation. J Am Heart Assoc, 2017, 6(12): e007597.
|
13. |
Zack CJ, Fender EA, Chandrashekar P, et al. National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol, 2017, 70(24): 2953-2960.
|
14. |
Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol, 2021, 77(4): e25-e197.
|
15. |
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2022, 43(7): 561-632.
|
16. |
Asmarats L, Puri R, Latib A, et al. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. J Am Coll Cardiol, 2018, 71(25): 2935-2956.
|
17. |
Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol, 2019, 74(24): 2998-3008.
|
18. |
LaPar DJ, Likosky DS, Zhang M, et al. Development of a risk prediction model and clinical risk score for isolated tricuspid valve surgery. Ann Thorac Surg, 2018, 106(1): 129-136.
|
19. |
Martin AP, Bartels M, Hauss J, et al. Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc, 2007, 39(10): 3169-3174.
|
20. |
Xu H, Wang H, Chen S, et al. Prognostic value of modified model for end-stage liver disease score in patients undergoing isolated tricuspid valve replacement. Front Cardiovasc Med, 2022, 9: 932142.
|
21. |
Dreyfus J, Audureau E, Bohbot Y, et al. TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery. Eur Heart J, 2022, 43(7): 654-662.
|
22. |
Schofer J, Tiburtius C, Hammerstingl C, et al. Transfemoral tricuspid valve repair using a percutaneous mitral valve repair system. J Am Coll Cardiol, 2016, 67(7): 889-890.
|
23. |
Taramasso M, Alessandrini H, Latib A, et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international TriValve registry. JACC Cardiovasc Interv, 2019, 12(2): 155-165.
|
24. |
Mehr M, Taramasso M, Besler C, et al. 1-year outcomes after edge-to-edge valve repair for symptomatic tricuspid regurgitation: results from the TriValve registry. JACC Cardiovasc Interv, 2019, 12(15): 1451-1461.
|
25. |
Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet, 2019, 394(10213): 2002-2011.
|
26. |
Lurz P, Stephan von Bardeleben R, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol, 2021, 77(3): 229-239.
|
27. |
Asmarats L, Perlman G, Praz F, et al. Long-term outcomes of the FORMA transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation: insights from the first-in-human experience. JACC Cardiovasc Interv, 2019, 12(15): 1438-1447.
|
28. |
Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol, 2021, 77(4): 345-356.
|
29. |
Hahn RT, Meduri CU, Davidson CJ, et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. J Am Coll Cardiol, 2017, 69(14): 1795-1806.
|
30. |
DENTI P. 4Tech-clinical outcomes and current challenges. PCR London Valves. (2017-09-26)[2022-07-01]. https://www.pcronline.com/Cases-resources-images/Resources/Course-videos-slides/2017/RAPID-FIRE-innovations-in-percutaneous-tricuspid-intervention?auth=true.
|
31. |
Nickenig G, Weber M, Schueler R, et al. 6-month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. J Am Coll Cardiol, 2019, 73(15): 1905-1915.
|
32. |
Curio J, Demir OM, Pagnesi M, et al. Update on the current landscape of transcatheter options for tricuspid regurgitation treatment. Interv Cardiol, 2019, 14(2): 54-61.
|
33. |
Rogers JH, Boyd WD, Bolling SF. Tricuspid annuloplasty with the Millipede ring. Prog Cardiovasc Dis, 2019, 62(6): 486-487.
|
34. |
Pan W, Long Y, Zhang X, et al. Feasibility study of a novel transcatheter tricuspid annuloplasty system in a porcine model. JACC Basic Transl Sci, 2022, 7(6): 600-607.
|
35. |
Asmarats L, Dagenais F, Bédard E, et al. Transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation: initial experience with the navigate bioprosthesis. Can J Cardiol, 2018, 34(10): 1370.e5-1370.e7.
|
36. |
Navia JL, Kapadia S, Elgharably H, et al. First-in-human implantations of the navigate bioprosthesis in a severely dilated tricuspid annulus and in a failed tricuspid annuloplasty ring. Circ Cardiovasc Interv, 2017, 10(12): e005840.
|
37. |
Hahn RT, George I, Kodali SK, et al. Early single-site experience with transcatheter tricuspid valve replacement. JACC Cardiovasc Imaging, 2019, 12(3): 416-429.
|
38. |
Fam NP, von Bardeleben RS, Hensey M, et al. Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv, 2021, 14(5): 501-511.
|
39. |
Lu F, Qiao F, Lv Y, et al. A radial force-independent bioprosthesis for transcatheter tricuspid valve implantation in a preclinical model. Int J Cardiol, 2020, 319: 120-126.
|
40. |
Lu FL, Ma Y, An Z, et al. First-in-Man experience of transcatheter tricuspid valve replacement with LuX-valve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv, 2020, 13(13): 1614-1616.
|
41. |
Lauten A, Ferrari M, Hekmat K, et al. Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation. Eur Heart J, 2011, 32(10): 1207-1213.
|
42. |
Lauten A, Figulla HR, Unbehaun A, et al. Interventional treatment of severe tricuspid regurgitation: early clinical experience in a multicenter, observational, first-in-man study. Circ Cardiovasc Interv, 2018, 11(2): e006061.
|
43. |
Estévez-Loureiro R, Sánchez-Recalde A, Amat-Santos IJ, et al. 6-month outcomes of the TricValve System in patients with tricuspid regurgitation: the TRICUS EURO study. JACC Cardiovasc Interv, 2022, 15(13): 1366-1377.
|